In last trading session, Exagen Inc (NASDAQ:XGN) saw 80710.0 shares changing hands with its beta currently measuring 1.42. Company’s recent per share price level of $3.29 trading at $0.02 or 0.61% at ring of the bell on the day assigns it a market valuation of $58.02M. That closing price of XGN’s stock is at a discount of -89.06% from its 52-week high price of $6.22 and is indicating a premium of 60.49% from its 52-week low price of $1.30. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.22 million shares which gives us an average trading volume of 112.76K if we extend that period to 3-months.
For Exagen Inc (XGN), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.33. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.25 in the current quarter.
Exagen Inc (NASDAQ:XGN) trade information
Upright in the green during last session for gaining 0.61%, in the last five days XGN remained trading in the red while hitting it’s week-highest on Thursday, 01/02/25 when the stock touched $3.29 price level, adding 23.13% to its value on the day. Exagen Inc’s shares saw a change of -19.76% in year-to-date performance and have moved -19.76% in past 5-day. Exagen Inc (NASDAQ:XGN) showed a performance of -27.69% in past 30-days. Number of shares sold short was 52214.0 shares which calculate 3.12 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 5 to the stock, which implies a rise of 34.2% to its current value. Analysts have been projecting 5 as a low price target for the stock while placing it at a high target of 5. It follows that stock’s current price would drop -51.98% in reaching the projected high whereas dropping to the targeted low would mean a loss of -51.98% for stock’s current value.
Exagen Inc (XGN) estimates and forecasts
Statistics highlight that Exagen Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 76.88% of value to its shares in past 6 months, showing an annual growth rate of 35.07% while that of industry is 12.30. Apart from that, the company came raising its revenue forecast for fiscal year 2025. This year revenue growth is estimated to rise 5.67% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 13.63M for the same. And 5 analysts are in estimates of company making revenue of 14.66M in the next quarter. Company posted 13.77M and 14.41M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 2.69% during past 5 years.
Exagen Inc (NASDAQ:XGN)’s Major holders
Insiders are in possession of 29.74% of company’s total shares while institution are holding 57.22 percent of that, with stock having share float percentage of 81.43%. Investors also watch the number of corporate investors in a company very closely, which is 57.22% institutions for Exagen Inc that are currently holding shares of the company. RTW INVESTMENTS, LP is the top institutional holder at XGN for having 1.51 million shares of worth $2.75 million. And as of 2024-06-30, it was holding 8.4253 of the company’s outstanding shares.
The second largest institutional holder is COWEN AND COMPANY, LLC, which was holding about 0.89 million shares on 2024-06-30. The number of shares represents firm’s hold over 4.9674 of outstanding shares, having a total worth of $1.62 million.
